102
Participants
Start Date
July 6, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
APG-115
APG-115 orally once daily from Days 1 to 7 every 28 days.
Azacitidine
75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
Cytarabine
1g/m\^2 IV QD on Days 3-7 (28-day cycle)
NOT_YET_RECRUITING
The First Hospital of Peking University, Beijing
NOT_YET_RECRUITING
The First Affilated Hospital of Ganzhou Medical University, Suzhou
RECRUITING
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
Guangzhou panyu central hospital, Guangzhou
RECRUITING
Nanfang Hospital of Southern Medical University, Guangzhou
RECRUITING
Henan Provincial Oncology Hospital, Zhengzhou
RECRUITING
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
The First affiliated hospital of Soochow University, Suzhou
RECRUITING
First Hospital of Jilin University, Changchun
RECRUITING
Shanghai Jiao Tong University school of medicine Ruijing Hospital, Shanghai
RECRUITING
Shanghai Sixth people's Hospital, Shanghai
Lead Sponsor
Suzhou Yasheng Pharmaceutical Co., Ltd.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY